Scarica l'app Stockscreener
28.63
3.51%
-1.04
Pre-mercato:
29.55
0.92
+3.21%
Precedente Chiudi:
$29.67
Aprire:
$29.65
Volume 24 ore:
864.86K
Relative Volume:
3.19
Capitalizzazione di mercato:
$1.43B
Reddito:
$345.60M
Utile/perdita netta:
$-79.01M
Rapporto P/E:
-17.84
EPS:
-1.6045
Flusso di cassa netto:
$-18.62M
1 W Prestazione:
-2.35%
1M Prestazione:
-2.52%
6M Prestazione:
-8.27%
1 anno Prestazione:
-54.51%
Intervallo 1D:
$28.39
$29.67
Intervallo di 1 settimana:
$28.00
$30.50
Portata 52W:
$27.19
$64.47
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Nome
Immunocore Holdings Plc Adr
Settore
Industria
Telefono
01235 5430281
Indirizzo
90 PARK DRIVE, OXFORDSHIRE
Confronta IMCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
28.63 | 1.43B | 345.60M | -79.01M | -18.62M | -1.6045 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-10-24 | Iniziato | UBS | Sell |
| 2024-10-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-13 | Iniziato | Needham | Buy |
| 2023-08-16 | Iniziato | CapitalOne | Overweight |
| 2023-07-17 | Iniziato | Canaccord Genuity | Hold |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-03-30 | Iniziato | Guggenheim | Buy |
| 2023-03-24 | Iniziato | Bryan Garnier | Buy |
| 2022-12-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-30 | Iniziato | Barclays | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-08-08 | Iniziato | Cowen | Outperform |
| 2022-08-02 | Iniziato | BTIG Research | Buy |
| 2022-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-20 | Iniziato | Oppenheimer | Outperform |
| 2021-03-02 | Iniziato | Goldman | Neutral |
| 2021-03-02 | Iniziato | JP Morgan | Overweight |
| 2021-03-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunocore Holdings Plc Adr Borsa (IMCR) Ultime notizie
Do investors need to be concerned about Immunocore Holdings plc ADR (IMCR)? - US Post News
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? - MSN
Immunocore holdings sees $23.99 million in stock purchases by Baker Bros - Investing.com South Africa
Immunocore amends senior notes indenture, files prospectus - Investing.com India
Immunocore amends senior notes indenture, files prospectus By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: biotech firm’s stock outlook amid HIV and cancer drug progress - Investing.com India
BTIG maintains Immunocore stock Buy rating, $91 target - Investing.com
Immunocore stock hits 52-week low at $27.59 amid market challenges - Investing.com
Immunocore stock hits 52-week low at $27.59 amid market challenges By Investing.com - Investing.com South Africa
Immunocore reports promising HIV trial results By Investing.com - Investing.com South Africa
Immunocore reports promising HIV trial results - Investing.com India
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - GlobeNewswire Inc.
Immunocore at TD Cowen Conference: Strategic Growth and Innovation - Investing.com India
Immunocore at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
Earnings call transcript: Immunocore Holdings Q4 2024 misses EPS - Investing.com
Immunocore Holdings earnings missed by $0.23, revenue fell short of estimates - Investing.com
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store? - MSN
A stock that deserves closer examination: Empresa Distribuidora y Comercial Norte S.A. ADR (EDN) - US Post News
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade - Yahoo Finance
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why - Zacks Investment Research
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Yahoo Finance
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer - Yahoo Finance
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term - Yahoo Finance
Disappointing data leads to Immunocore stock downgrade by Morgan Stanley - Investing.com South Africa
Immunocore stock hits 52-week low at $29.23 amid market challenges - Investing.com
Immunocore's SWOT analysis: TCR pioneer's stock faces pivotal year - Investing.com
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy - Yahoo Finance
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - Yahoo Finance
New Strong Buy Stocks for December 12th - Yahoo Finance
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals - Yahoo Finance
RZLT Stock Rises On FDA's Orphan Designation For Rare Disease Drug - Barchart
SNTI Stock Skyrockets On Initial Data From Phase I Cancer Study - Barchart
Altimmune Stock Up More Than 25% In A Month: Here's Why - Barchart
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect? - MSN
Mirum Shares Surge More Than 90% in 6 Months: Here's Why - Yahoo Finance
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know - MSN
New Strong Buy Stocks for November 26th - Yahoo Finance
Stack Capital Group announces normal course issuer bid - MSN
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Barchart
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Nasdaq
What will it take for small caps to finally outperform large caps on earnings, performance? - MSN
Immunocore (IMCR) Upgraded to Buy: Here's Why - MSN
Immunocore's SWOT analysis: biotech stock faces pivotal moment amid PRAME data - Investing.com India
FATE Q3 Earnings Beat On Higher Revenues, Pipeline In Focus - Barchart
Immunocore Holdings Plc Adr Azioni (IMCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.89%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):